Alexandria Forbes, MeiraGTx CEO (Hollie Adams/Bloomberg via Getty Images)
J&J buys eye disease gene therapy from MeiraGTx, giving the biotech the cash infusion it was seeking
Johnson & Johnson purchased a gene therapy for X-linked retinitis pigmentosa from MeiraGTx for $65 million upfront, the biotech announced Thursday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.